Perrigo Co. (PRGO) said it has received final approval from the FDA for its abbreviated new drug application, or ANDA, for calcium acetate capsules, the generic equivalent of Phoslo Gelcaps.
Phoslo Gelcaps are indicated for hyperphosphatemia in patients with end stage kidney disease who are on dialysis.
Perrigo was previously in patent litigation over this product with the brand and the litigation settled in late 2011. The terms of the settlement are confidential.
For comments and feedback: editorial@rttnews.com